Adcendo

About Adcendo

Adcendo is a clinical-stage biotech company focused on developing first-in-class and best-in-class antibody-drug conjugates (ADCs) for targeted cancer treatment. The company operates globally, with research and development activities aimed at oncologic indications, including mesenchymal cancers and soft tissue sarcomas, through an end-to-end ADC platform. Adcendo is headquartered in Copenhagen, Denmark, and communicates progress through milestones such as phase I/II trials and FDA Fast Track designations.